This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumoto, S.
Right arrow Articles by Kuwahara, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumoto, S.
Right arrow Articles by Kuwahara, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2000, p. 619-621, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Pulmonary Aspergillosis

Satoru Matsumoto,1 Yoshimi Wakai,1 Toru Nakai,1 Kazuo Hatano,1 Tomoe Ushitani,1 Fumiaki Ikeda,1,* Shuichi Tawara,1 Toshio Goto,1 Fumio Matsumoto,2 and Shogo Kuwahara3

Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima, Yodogawa-ku, Osaka 532-8514,1 Kanagawa Prefectural Nursing and Hygienic School Hospital, 1-6, Shiomidai, Isogo-ku, Yokohama 235-0022,2 and Toho University School of Medicine, Ohmori Nishi, Ohta-ku, Tokyo 143-8540,3 Japan

Received 3 May 1999/Returned for modification 26 July 1999/Accepted 10 December 1999

The efficacy of FK463, a novel water-soluble lipopeptide, was evaluated in mouse models of pulmonary aspergillosis and was compared with that of amphotericin B (AMPH-B). In the pulmonary aspergillosis models induced by intranasal inoculation, FK463 exhibited good efficacy, with 50% effective doses in the range of 0.26 to 0.51 mg/kg of body weight; these values were comparable to those of AMPH-B. In an Aspergillus target organ assay with immunosuppressed mice, under conditions of constant plasma levels of FK463, using a subcutaneously implanted osmotic pressure pump, a significant reduction in viable fungal cells was observed at plasma FK463 levels of 0.55 to 0.80 µg/ml or higher. We conclude that FK463 is highly effective in the treatment of pulmonary aspergillosis in this animal model. These results indicate that FK463 may be a potent parenterally administered antifungal agent for pulmonary aspergillosis.


* Corresponding author. Mailing address: Department of Infectious Diseases, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome, Kashima, Yodogawa-Ku, Osaka 532-8514, Japan. Phone: 81-6-6390-1158. Fax: 81-6-6304-5367. E-mail: fumiaki_ikeda{at}po.fujisawa.co.jp.


Antimicrobial Agents and Chemotherapy, March 2000, p. 619-621, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Kakeya, H., Miyazaki, Y., Senda, H., Kobayashi, T., Seki, M., Izumikawa, K., Yanagihara, K., Yamamoto, Y., Tashiro, T., Kohno, S. (2008). Efficacy of SPK-843, a Novel Polyene Antifungal, in Comparison with Amphotericin B, Liposomal Amphotericin B, and Micafungin against Murine Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 52: 1868-1870 [Abstract] [Full Text]  
  • Keirns, J., Sawamoto, T., Holum, M., Buell, D., Wisemandle, W., Alak, A. (2007). Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults. Antimicrob. Agents Chemother. 51: 787-790 [Abstract] [Full Text]  
  • Clemons, K. V., Espiritu, M., Parmar, R., Stevens, D. A. (2005). Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis. Antimicrob. Agents Chemother. 49: 4867-4875 [Abstract] [Full Text]  
  • Seibel, N. L., Schwartz, C., Arrieta, A., Flynn, P., Shad, A., Albano, E., Keirns, J., Lau, W. M., Facklam, D. P., Buell, D. N., Walsh, T. J. (2005). Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients. Antimicrob. Agents Chemother. 49: 3317-3324 [Abstract] [Full Text]  
  • Hiemenz, J., Cagnoni, P., Simpson, D., Devine, S., Chao, N., Keirns, J., Lau, W., Facklam, D., Buell, D. (2005). Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant. Antimicrob. Agents Chemother. 49: 1331-1336 [Abstract] [Full Text]  
  • Graybill, J. R., Bocanegra, R., Gonzalez, G. M., Najvar, L. K. (2003). Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 52: 656-662 [Abstract] [Full Text]  
  • Watabe, E., Nakai, T., Matsumoto, S., Ikeda, F., Hatano, K. (2003). Killing Activity of Micafungin against Aspergillus fumigatus Hyphae Assessed by Specific Fluorescent Staining for Cell Viability. Antimicrob. Agents Chemother. 47: 1995-1998 [Abstract] [Full Text]  
  • Nakai, T., Uno, J., Ikeda, F., Tawara, S., Nishimura, K., Miyaji, M. (2003). In Vitro Antifungal Activity of Micafungin (FK463) against Dimorphic Fungi: Comparison of Yeast-Like and Mycelial Forms. Antimicrob. Agents Chemother. 47: 1376-1381 [Abstract] [Full Text]  
  • Luque, J. C., Clemons, K. V., Stevens, D. A. (2003). Efficacy of Micafungin Alone or in Combination against Systemic Murine Aspergillosis. Antimicrob. Agents Chemother. 47: 1452-1455 [Abstract] [Full Text]  
  • Warn, P. A., Morrissey, G., Morrissey, J., Denning, D. W. (2003). Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 51: 913-919 [Abstract] [Full Text]  
  • Petraitis, V., Petraitiene, R., Groll, A. H., Roussillon, K., Hemmings, M., Lyman, C. A., Sein, T., Bacher, J., Bekersky, I., Walsh, T. J. (2002). Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 46: 1857-1869 [Abstract] [Full Text]  
  • Chiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R., Walsh, T. J. (2001). Synergy, Pharmacodynamics, and Time-Sequenced Ultrastructural Changes of the Interaction between Nikkomycin Z and the Echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother. 45: 3310-3321 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Ibrahim, K. H., Piscitelli, S. C., Bekersky, I., Walsh, T. J. (2001). Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits. Antimicrob. Agents Chemother. 45: 3322-3327 [Abstract] [Full Text]  
  • Bowman, J. C., Abruzzo, G. K., Anderson, J. W., Flattery, A. M., Gill, C. J., Pikounis, V. B., Schmatz, D. M., Liberator, P. A., Douglas, C. M. (2001). Quantitative PCR Assay To Measure Aspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate. Antimicrob. Agents Chemother. 45: 3474-3481 [Abstract] [Full Text]